Professor Shen Jingshan obtained his Master's degree in Medicinal Chemistry from China Pharmaceutical University in 1995 under the supervision of Professor Shuzi Tu. He earned his Ph.D. in Organic Chemistry from the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS) in 1998, mentored by Academician Ruyun Ji, and has since been with the Institute. Currently, he serves principal investigator and doctoral supervisor in SIMM, CAS.

With an approach on collaborative innovation among industry and academia, he has established an integrated engineering system for drug R&D and manufacturing that ensures operations across the entire continuum with high quality and efficiency, and enables the rapid research and manufacturing of drugs in emergency situations. as well as the reserve of candidate drugs and technologies for emerging and sudden viral infections. Jointly established. the Central Asia Centre of Drug Discovery and Development of CAS, on behalf of the Institute.

Among the drug discovery projects led by Professor Shen, VV116 (Mindvy®) and VV934 (Xiannuoxin®) are currently the only two regularly approved antiviral agents for COVID-19 in China, and VV116 also has been approved in Uzbekistan for COVID-19 in 2021; TPN171 (Onvita®) have been approved for the treatment of male erectile dysfunction (ED) in both Uzbekistan (2022) and China (2025); The phase II clinical trial of VV116 for the treatment of respiratory syncytial virus (RSV) infection has been completed; Additionally, several other candidate drugs are at different stages of clinical research in China.

His group has established an innovation platform for generating green and sustainable API production technology underpinned by a “Control from Root Design” strategy. This strategy prioritizes the design and evaluation of the reactions and synthetic routes from the very beginning of a project under the principle of green and sustainable chemistry with the concepts of safety, environmental protection, operational simplicity, and low material input, and is dedicated to innovate or develop route of synthesis and process technologies with distinct competitive advantages that effectively eliminate safety hazards and minimize adverse impacts on human health and the environment.

Education Experience： 

1995.09 - 1998.07 Ph.D. degree in Organic Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

1992.09 - 1995.07 Master degree in Medicinal Chemistry, China Pharmaceutical University

Work Experience： 

2006-Present  Professor and Principal Investigator, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 

2001-2005  Associated Professor and Principal Investigator, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 

1998-2000  Assistant Professor, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences